EGFR and non-small cell lung carcinoma: Osimertinib has been approved by U.S. FDA and China National Medical Products Administration (NMPA) as the adjuvant treatment in resected early-stage EGFR-classical mutated NSCLC based on the clinical study of ADAURA (Herbst et al., 2023).